JP2025503502A5 - - Google Patents

Info

Publication number
JP2025503502A5
JP2025503502A5 JP2024538291A JP2024538291A JP2025503502A5 JP 2025503502 A5 JP2025503502 A5 JP 2025503502A5 JP 2024538291 A JP2024538291 A JP 2024538291A JP 2024538291 A JP2024538291 A JP 2024538291A JP 2025503502 A5 JP2025503502 A5 JP 2025503502A5
Authority
JP
Japan
Application number
JP2024538291A
Other languages
Japanese (ja)
Other versions
JP2025503502A (ja
JPWO2023118507A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/087613 external-priority patent/WO2023118507A2/en
Publication of JP2025503502A publication Critical patent/JP2025503502A/ja
Publication of JP2025503502A5 publication Critical patent/JP2025503502A5/ja
Publication of JPWO2023118507A5 publication Critical patent/JPWO2023118507A5/ja
Pending legal-status Critical Current

Links

JP2024538291A 2021-12-22 2022-12-22 化合物及びhdac6阻害剤としてのその使用 Pending JP2025503502A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21217182.1 2021-12-22
EP21217181.3 2021-12-22
EP21217181 2021-12-22
EP21217182 2021-12-22
PCT/EP2022/087613 WO2023118507A2 (en) 2021-12-22 2022-12-22 Compounds and use thereof as hdac6 inhibitors

Publications (3)

Publication Number Publication Date
JP2025503502A JP2025503502A (ja) 2025-02-04
JP2025503502A5 true JP2025503502A5 (https=) 2026-01-07
JPWO2023118507A5 JPWO2023118507A5 (https=) 2026-01-07

Family

ID=84981649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538291A Pending JP2025503502A (ja) 2021-12-22 2022-12-22 化合物及びhdac6阻害剤としてのその使用

Country Status (9)

Country Link
US (2) US20250051319A1 (https=)
EP (1) EP4452265A2 (https=)
JP (1) JP2025503502A (https=)
KR (1) KR20240124952A (https=)
AU (1) AU2022420827A1 (https=)
CA (1) CA3239992A1 (https=)
IL (1) IL313636A (https=)
MX (1) MX2024007904A (https=)
WO (1) WO2023118507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
MX2024007904A (es) * 2021-12-22 2024-09-18 Augustine Therapeutics Compuestos y uso de estos como inhibidores de hdac6.
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
WO2024261327A1 (en) * 2023-06-21 2024-12-26 Augustine Therapeutics 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors
KR20260025099A (ko) * 2023-06-21 2026-02-23 어거스틴 테라퓨틱스 헤테로아릴-아민 화합물 및 이의 hdac6 억제제로서의 용도
WO2024261328A1 (en) * 2023-06-21 2024-12-26 Augustine Therapeutics Amide-amine compounds and use thereof as hdac6 inhibitors
WO2026027696A1 (en) * 2024-07-31 2026-02-05 Augustine Therapeutics Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
US20090023798A1 (en) 2007-06-15 2009-01-22 Pharmacyclics, Inc. Thiohydroxamates as inhibitors of histone deacetylase
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2800717A1 (en) * 2010-05-27 2011-12-01 Bayer Intellectual Property Gmbh Heterocyclic thiosubstituted alkanol derivatives as fungicides
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
JP6338601B2 (ja) 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
WO2017053360A1 (en) 2015-09-22 2017-03-30 The Board Of Trustees Of The University Of Illinois Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors
US11584733B2 (en) * 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
ES2749743B2 (es) 2018-09-21 2020-12-14 Consejo Superior Investigacion Derivados de purina inhibidores de cdc7 y su uso para el tratamiento de patologias neurologicas
WO2021133957A1 (en) * 2019-12-27 2021-07-01 Onkure, Inc. Benzimidazole compounds as hdac6 inhibitors
EP4111863A1 (en) 2021-07-02 2023-01-04 EuroChem Antwerpen Phosphorus use efficiency enhancers as plant growth promotors
MX2024007904A (es) * 2021-12-22 2024-09-18 Augustine Therapeutics Compuestos y uso de estos como inhibidores de hdac6.
US20240139187A1 (en) 2022-10-12 2024-05-02 The Children's Medical Center Corporation Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity

Similar Documents

Publication Publication Date Title
JP2025503502A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023010976A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BY13167U (https=)
BY13162U (https=)
CN307047765S (https=)
CN307045755S (https=)
CN307045696S (https=)
CN307045565S (https=)
CN307045282S (https=)
CN307044631S (https=)
CN307044544S (https=)
BY23965C1 (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)
BY13168U (https=)
CN307049634S (https=)